The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInduction Heal. Regulatory News (INHC)

Share Price Information for Induction Heal. (INHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.00
Bid: 11.00
Ask: 13.00
Change: 0.00 (0.00%)
Spread: 2.00 (18.182%)
Open: 12.00
High: 12.00
Low: 12.00
Prev. Close: 12.00
INHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Extension to 2022 annual reporting deadline

22 Sep 2022 07:00

RNS Number : 2297A
Induction Healthcare Group PLC
22 September 2022
 

 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Extension to publication deadline for Audited Final Results 

 

Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that following the grant by AIM Regulation of an extension to its 2022 annual reporting deadline, it now expects to report its final results for the year ended 31 March 2022 during October 2022, rather than on or before 30 September 2022.

 

The extension is required to complete the audit work for the year ended 31 March 2022 due to COVID related challenges and the impact it has had on resource availability to complete the required work.

FY22 Financial Performance

 

There is no change to the financial performance and, as previously reported on 21 April, results for FY22 are expected to be in-line with guidance. A significant increase in contracted annual recurring revenues ("ARR"), a key metric for the business, is expected to be delivered, with ARR for the full year of c. £15m (2021: £1.8m). Following upgraded market expectations adjusted EBITDA was at a breakeven level (2021 EBITDA loss: £4.1m) and net cash at 31 March 2022 was £7.5m (2021: £2.4m).

 

Following strong renewals of NHS England Induction Attend Anywhere ("AA") contracts, the majority with contracts renewed for 2 or 3 year terms, the Group's cash position has also increased significantly beyond period end levels.

 

James Balmain, CEO of Induction Healthcare, said: "FY22 was a transformational year for Induction following the acquisition of Attend Anywhere and this has continued to deliver into H1 FY23 with the AA contract renewals. I look forward to presenting our full results in October and remain confident in the future prospects of the Company, including trading for the current financial year." 

ENQUIRIES

 

Induction

James Balmain, Chief Executive Officer

Guy Mitchell, Chief Financial Officer

Via Walbrook PR Ltd: induction@walbrookpr.com

 

Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

Philip Davies / Kailey Aliyar

 

 

Walbrook PR Ltd 

induction@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44(0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About Induction - www.inductionhealthcare.com

 

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEFEEFEESESU
Date   Source Headline
29th Jan 20247:00 amRNSBlock listing Interim Review
7th Nov 20237:00 amRNSHalf-year Report
10th Oct 20237:00 amRNSUpdate on NHS National Portals Contracts
31st Jul 20233:13 pmRNSBlock listing Interim Review
31st Jul 20237:00 amRNSAudited Final Results
30th Jun 20237:00 amRNSBoard Changes and Trading Update
18th Apr 20237:00 amRNSTrading Update for year ending 31 March 2023
27th Jan 20237:00 amRNSBlock Listing Six Monthly Return
17th Jan 20237:00 amRNSChange of Registered Office
16th Jan 202312:20 pmRNSDirector/PDMR Shareholding
11th Jan 202312:52 pmRNSResults of 2022 Annual General Meeting
9th Jan 20237:00 amRNSDirectorate Changes
20th Dec 20227:00 amRNSNotice of AGM
20th Dec 20227:00 amRNSChange of Auditor
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
5th Dec 202211:05 amRNSSecond Price Monitoring Extn
5th Dec 202211:00 amRNSPrice Monitoring Extension
5th Dec 20227:01 amRNSDirectorate Changes
5th Dec 20227:00 amRNSHalf-year Report
29th Nov 202212:01 pmEQSInduction Healthcare Group focused on 'building out core capability'
28th Nov 20227:01 amRNSNotice of Half-year results
28th Nov 20227:00 amRNSAudited Final Results
24th Oct 20227:00 amRNSUpdate on publication of Audited Final Results
22nd Sep 20227:00 amRNSExtension to 2022 annual reporting deadline
27th Jul 202210:30 amRNSBlock Listing Six Monthly Return
11th Jul 20227:00 amRNSDistribution agreement for Zesty with System C
5th Jul 20227:01 amEQSEdison Investment Research Limited: Induction Healthcare Group (INHC) initiation – Evolving technology in healthcare
7th Jun 20227:00 amRNSDirectorate Change
31st May 202212:58 pmRNSHolding(s) in Company
4th May 20227:00 amRNSDirectorate Change
29th Apr 20227:00 amRNSTotal Voting Rights
21st Apr 20227:00 amRNSPost-period end Trading Update
13th Apr 20224:01 pmRNSHolding(s) in Company
12th Apr 20224:00 pmRNSPurchase of Shares by Director
12th Apr 202212:11 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSPurchase of Shares by Directors
11th Apr 20227:00 amRNSNHS England contract renewals secure £6.6m ARR
7th Apr 20229:27 amRNSHolding(s) in Company
4th Apr 20227:00 amRNSFour London NHS Trusts sign with Induction Zesty
30th Mar 202211:00 amRNSAIM Rule 17 Schedule 2(g) Update
21st Mar 20227:00 amRNSNHS Scotland & Scottish Govt. Contract Renewals
26th Jan 20227:00 amRNSBlock Listing Six Monthly Return
6th Dec 20217:00 amRNSInduction AA rolls out new services nationwide
2nd Dec 202112:20 pmRNSPurchase of Shares by Directors
2nd Dec 20217:00 amRNSUnaudited Interim Results
26th Nov 20217:00 amRNSNotice of Half-year Results
15th Nov 20217:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.